REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior year Achieved record... Read More

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2025 Unplugged Medtech and Life Sciences Access Day in New York on Thursday, February 27, 2025, at 8:00 AM PT / 11:00 AM ET. A live and archived webcast of the... Read More

REDWOOD CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Wednesday, February 19, 2025. Company management will host a conference call to discuss financial results beginning at 1:30... Read More

REDWOOD CITY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 36 th Annual Healthcare Conference in New York on Wednesday, December 4, 2024, at 9:30 AM PT / 12:30 PM ET. A live and archived webcast of the presentation will... Read More

Two New Programs Aim to Improve Awareness and Support for Patients with Severe COPD/Emphysema REDWOOD CITY, Calif. / Nov 19, 2024 / Business Wire / Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are continuing their ongoing collaboration with two new programs aimed at supporting patients with severe COPD and... Read More

REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, November 21, 2024. About Pulmonx Corporation Pulmonx Corporation (Nasdaq:... Read More

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Stifel 2024 Healthcare Conference in New York on Tuesday, November 19, 2024, at 6:10 AM PT / 9:10 AM ET. A live and archived webcast of the presentation will be available on... Read More

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights Achieved worldwide revenue of $20.4 million in the third quarter of 2024, a 15% increase over the same period last year Delivered... Read More

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m.... Read More

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits to patients treated with Zephyr® Valves REDWOOD CITY, Calif. & VIENNA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease,... Read More

REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8 th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024. About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global... Read More

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the 2024 Wells Fargo Healthcare Conference in Boston on Thursday, September 5, 2024, at 1:30 PM PT / 4:30 PM ET. A live and archived webcast of the presentation will be available... Read More

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights Achieved record worldwide revenue of $20.8 million in the second quarter of 2024, a 21% increase over the same period last year and an... Read More

REDWOOD CITY, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 44 th Annual Growth Conference in Boston. Management is scheduled to present on Tuesday, August 13, 2024, at 5:00 AM PT / 8:00 AM ET. A live and archived webcast of the... Read More

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2024 after the close of trading on Wednesday, July 31, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m.... Read More

REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a... Read More

REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Recent Highlights Recorded worldwide revenue of $18.9 million in the first quarter of 2024, a 30% increase over the same period last year and an increase of 29% on a... Read More

REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.... Read More

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company’s Interim Chief Financial Officer since October 10, 2023, and will transition to his... Read More

REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). On March 15, 2024, Pulmonx granted Mr. Williamson (i)... Read More

AeriSeal System Shows Promise in Limiting Collateral Ventilation, Potentially Enabling a Greater Number of Severe COPD/Emphysema Patients to Benefit from Treatment with Zephyr ® Valves, a Minimally Invasive Treatment Option REDWOOD CITY, Calif. / Feb 26, 2024 / Business Wire / Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for chronic obstructive pulmonary... Read More

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2023 ended December 31, 2023. Recent Highlights Delivered $68.7 million in worldwide revenue for the full year of 2023, a 28% increase over the prior year Achieved... Read More

REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company’s President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve... Read More

REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2023 after the close of trading on Wednesday, February 21, 2024. Company management will host a conference call to discuss financial results beginning at 1:30... Read More

REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Piper Sandler 35 th Annual Healthcare Conference in New York on Wednesday, November 29, 2023, at 11:00 AM PT / 2:00 PM ET. A live and archived webcast of the presentation will... Read More

REDWOOD CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the Stifel 2023 Healthcare Conference in New York on Tuesday, November 14, 2023, at 11:25am PT... Read More

REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2023 ended September 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.7 million in the third quarter of 2023, a 31% increase over the same period last year and an... Read More

Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial Officer Preliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 million Management to host conference call on October 30, 2023 to discuss third quarter 2023 financial results REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation... Read More

REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the 2023 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2023, at... Read More

REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last year Delivered... Read More

REDWOOD CITY, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 43 rd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 9, 2023, at 12:00 PM PT / 3:00 PM ET. A live and archived webcast of the... Read More

REDWOOD CITY, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2023 after the close of trading on Wednesday, August 2, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m.... Read More

REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2023 ended March 31, 2023. Recent Highlights Recorded worldwide revenue of $14.5 million in the first quarter of 2023, a 35% increase over the same period last year and an increase of... Read More

REDWOOD CITY, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023, at 3:55 PM PT / 6:55 PM ET. A live and archived webcast of the presentation will be available on... Read More

REDWOOD CITY, Calif. / Apr 18, 2023 / Business Wire / Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2023 after the close of trading on Tuesday, May 2, 2023. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A... Read More

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31, 2022. Recent Highlights Delivered $53.7 million in worldwide revenue for the full year of 2022 Achieved record worldwide revenue of $15.4... Read More

REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conference in New York on Thursday, March 2, 2023, at 10:15 AM PT / 1:15 PM ET. A live and archived webcast of the presentation will be available on... Read More

REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the close of trading on Wednesday, February 22, 2023. Company management will host a conference call to discuss financial results beginning at 1:30... Read More